Menu
Recruiting NCT07449195

A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors

No phase Interventional Ocular Tumor

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Intalight Dream OCT, Heidelberg Spectralis OCT.
Who it may be relevant to
Registry conditions: Ocular Tumor. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Ocular Imaging for Monitoring of Ocular Tumor Disease

Overview

The purpose of this study is to compare two devices used for optical coherence tomography (OCT). OCT is a noninvasive imaging (scanning) method that uses reflected light to create pictures of the back of the eye, and doctors can use OCT to detect and monitor different types of cancer

Interventions

  • Diagnostic test Intalight Dream OCT
    This is a next-generation swept-source device that has a faster imaging speed and higher sensitivity than the previous generation of frequency-domain OCT devices, which serve as the current standard of care devices.
  • Diagnostic test Heidelberg Spectralis OCT
    This is the standard of care for optical imaging.

Primary outcome measures

  • Image quality for participants [Time frame: Up to 1 year]
  • Field of view for participants [Time frame: Up to 1 year]

Eligibility criteria

Inclusion criteria

  • Age ≥18 years.
  • At least 1 eye that has an intraocular or ocular surface tumor.
  • The presence of a natural crystalline lens or intraocular lens.
  • Pupils that can dilate up to at least 3 mm in the study eyes.
  • The absence of opaque natural crystalline lenses or the presence of any ocular disease that prevents the view of the retina for imaging.
  • Patients must be able to fixate on the imaging target.
  • Patients must be able to sit still for a period of time (approximately 2 minutes).

Exclusion criteria

  • Does not meet ALL of the above conditions

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

United States · 7 centers
  • Memorial Sloan Kettering at Basking Ridge (Consent Only) — Basking Ridge
  • Memorial Sloan Kettering Monmouth (Consent only) — Middletown
  • Memorial Sloan Kettering Bergen (Consent Only) — Montvale
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only) — Commack
  • Memorial Sloan Kettering Westchester (Consent Only) — Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites) — New York
  • Memorial Sloan Kettering Cancer Center @ Nassau (Consent only) — Uniondale

Identifiers

NCT: NCT07449195 · 25-314

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗